Geode Capital Management LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 0.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 912,538 shares of the company's stock after purchasing an additional 4,079 shares during the period. Geode Capital Management LLC owned about 1.88% of Axsome Therapeutics worth $77,228,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of AXSM. Franklin Resources Inc. lifted its stake in Axsome Therapeutics by 13.6% in the 4th quarter. Franklin Resources Inc. now owns 182,290 shares of the company's stock valued at $15,424,000 after purchasing an additional 21,756 shares during the last quarter. Intrust Bank NA lifted its stake in shares of Axsome Therapeutics by 6.9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company's stock valued at $239,000 after acquiring an additional 183 shares during the last quarter. DnB Asset Management AS lifted its stake in shares of Axsome Therapeutics by 1,100.7% in the 4th quarter. DnB Asset Management AS now owns 73,770 shares of the company's stock valued at $6,242,000 after acquiring an additional 67,626 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in shares of Axsome Therapeutics by 19.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 4,678 shares of the company's stock valued at $396,000 after acquiring an additional 761 shares in the last quarter. Finally, Norges Bank bought a new stake in Axsome Therapeutics during the 4th quarter worth $34,100,000. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Stock Up 0.2 %

Shares of AXSM traded up $0.22 during trading hours on Thursday, hitting $104.69. The stock had a trading volume of 74,349 shares, compared to its average volume of 679,178. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The firm has a market capitalization of $5.10 billion, a P/E ratio of -17.51 and a beta of 0.88. The firm has a 50 day simple moving average of $119.16 and a 200-day simple moving average of $102.20. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXSM has been the topic of a number of recent research reports. Needham & Company LLC reissued a "buy" rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $200.00 target price on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Mizuho upped their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. Bank of America raised their price target on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, Robert W. Baird boosted their price objective on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $169.80.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 22.40% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.